Skip to main content
Erschienen in:

02.01.2019 | Original Article – Clinical Oncology

FDG PET/CT to predict the curability of endoscopic resection for early gastric cancer

verfasst von: Hyun Woo Chung, Jeong Hwan Kim, In-Kyung Sung, Sun-Young Lee, Hyung Seok Park, Chan Sup Shim, Ho Yoon Bang, Young So, Eun Jeong Lee

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We evaluated the value of fluorine-18 fluorodeoxyglucose positron-emission tomography/computed tomography (FDG PET/CT) as a complementary imaging modality to endoscopy to predict the curability of endoscopic submucosal dissection (ESD) for early gastric cancer (EGC).

Methods

The institutional review board approved this retrospective study with a waiver of informed consent. The records of patients who underwent FDG PET/CT for initial routine staging of gastric cancer from January 2012 to October 2017 were reviewed retrospectively. Among them, the patients who had EGC with well or moderately differentiated adenocarcinoma were included in this study. A total of 210 EGCs in 199 patients (mean age ± SD, 67 ± 10 years) were selected for this study. For the analysis of FDG PET/CT image, the radiotracer uptake by the primary tumor was compared with the background gastric uptake. Each case was classified as curable by ESD (no discrete radioactivity) and not curable by ESD (discrete radioactivity).

Results

The detection rate of EGC by FDG PET/CT was 37.1% (78 discrete radioactivity in 210 EGCs). However, for the detection of EGC that is not curable by ESD, the sensitivity, specificity, positive predictive value, negative predictive value, and area under the receiver operating characteristic curve with 95% confidence intervals were 79% (67–87%), 91% (85–95%), 81% (71–88%), 89% (84–93%), and 0.85 (0.79–0.89), respectively.

Conclusion

FDG PET/CT may be a useful complementary imaging modality to endoscopy to predict the curability of ESD for EGC.
Literatur
Zurück zum Zitat Lee EJ, Chang SH, Lee TY, Yoon SY, Cheon YK, Shim CS et al (2015) Prognostic value of FDG-PET/CT total lesion glycolysis for patients with resectable distal bile duct adenocarcinoma. Anticancer Res 35(12):6985–6991PubMed Lee EJ, Chang SH, Lee TY, Yoon SY, Cheon YK, Shim CS et al (2015) Prognostic value of FDG-PET/CT total lesion glycolysis for patients with resectable distal bile duct adenocarcinoma. Anticancer Res 35(12):6985–6991PubMed
Zurück zum Zitat Margulies C, Krevsky B, Catalano MF (1994) How accurate are endoscopic estimates of size? Gastrointest Endosc 40(2 Pt 1):174–177CrossRefPubMed Margulies C, Krevsky B, Catalano MF (1994) How accurate are endoscopic estimates of size? Gastrointest Endosc 40(2 Pt 1):174–177CrossRefPubMed
Zurück zum Zitat Ono H, Kondo H, Gotoda T, Shirao K, Yamaguchi H, Saito D et al (2001) Endoscopic mucosal resection for treatment of early gastric cancer. Gut 48(2):225–229CrossRefPubMedPubMedCentral Ono H, Kondo H, Gotoda T, Shirao K, Yamaguchi H, Saito D et al (2001) Endoscopic mucosal resection for treatment of early gastric cancer. Gut 48(2):225–229CrossRefPubMedPubMedCentral
Zurück zum Zitat Shoda H, Kakugawa Y, Saito D, Kozu T, Terauchi T, Daisaki H et al (2007) Evaluation of 18F-2-deoxy-2-fluoro-glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy. Br J Cancer 97(11):1493–1498CrossRefPubMedPubMedCentral Shoda H, Kakugawa Y, Saito D, Kozu T, Terauchi T, Daisaki H et al (2007) Evaluation of 18F-2-deoxy-2-fluoro-glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy. Br J Cancer 97(11):1493–1498CrossRefPubMedPubMedCentral
Zurück zum Zitat Vakil N, Smith W, Bourgeois K, Everbach EC, Knyrim K (1994) Endoscopic measurement of lesion size: Improved accuracy with image processing. Gastrointest Endosc 40(2 Pt 1):178–183CrossRefPubMed Vakil N, Smith W, Bourgeois K, Everbach EC, Knyrim K (1994) Endoscopic measurement of lesion size: Improved accuracy with image processing. Gastrointest Endosc 40(2 Pt 1):178–183CrossRefPubMed
Zurück zum Zitat Yao K, Yao T, Matsui T, Iwashita A, Oishi T (2000) Hemoglobin content in intramucosal gastric carcinoma as a marker of histologic differentiation: a clinical application of quantitative electronic endoscopy. Gastrointest Endosc 52(2):241–245CrossRefPubMed Yao K, Yao T, Matsui T, Iwashita A, Oishi T (2000) Hemoglobin content in intramucosal gastric carcinoma as a marker of histologic differentiation: a clinical application of quantitative electronic endoscopy. Gastrointest Endosc 52(2):241–245CrossRefPubMed
Zurück zum Zitat Yao K, Oishi T, Matsui T, Yao T, Iwashita A (2002a) Novel magnified endoscopic findings of microvascular architecture in intramucosal gastric cancer. Gastrointest Endosc 56(2):279–284CrossRefPubMed Yao K, Oishi T, Matsui T, Yao T, Iwashita A (2002a) Novel magnified endoscopic findings of microvascular architecture in intramucosal gastric cancer. Gastrointest Endosc 56(2):279–284CrossRefPubMed
Metadaten
Titel
FDG PET/CT to predict the curability of endoscopic resection for early gastric cancer
verfasst von
Hyun Woo Chung
Jeong Hwan Kim
In-Kyung Sung
Sun-Young Lee
Hyung Seok Park
Chan Sup Shim
Ho Yoon Bang
Young So
Eun Jeong Lee
Publikationsdatum
02.01.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 3/2019
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-018-02832-9

Weitere Artikel der Ausgabe 3/2019

Journal of Cancer Research and Clinical Oncology 3/2019 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mit dem Alkoholentzug sinkt das Krebsrisiko

Wie die Ergebnisse einer Studie aus Frankreich nahelegen, kann sich das Risiko von alkoholabhängigen Menschen, an einem alkoholassoziierten Tumor zu erkranken, um rund 40% vermindern, wenn sie das Trinken reduzieren oder ganz einstellen.

Gemischte Befunde zur zielgerichteten Adjuvanz

23.07.2024 Melanom Nachrichten

Mit Blick auf rezidiv- und metastasenfreies Überleben bestätigen die finalen Ergebnisse der COMBI-AD-Studie die Wirksamkeit von Dabrafenib/Trametinib beim Stadium-III-Melanom. Die Effekte auf das Gesamtüberleben sind dagegen weniger klar.  

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.